New Launch24 Jun 2025, 05:01 pm
Aurobindo Pharma Subsidiary CuraTeQ Biologics Receives Approval for Biosimilar Dyrupeg in UK
AI Summary
CuraTeQ Biologics s.r.o, a wholly owned step-down subsidiary of Aurobindo Pharma Ltd, has obtained marketing authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for Dyrupeg™, its pegylated filgrastim biosimilar version. This marks the third biosimilar approval by MHRA for CuraTeQ, following Bevgolva™ in December 2024 and Zefylti™ in May 2025. Earlier in April 2025, Dyrupeg™ received marketing authorization in the European Union from the European Commission (EC).
Key Highlights
- CuraTeQ Biologics s.r.o, a subsidiary of Aurobindo Pharma Ltd, received approval for biosimilar Dyrupeg™ from UK's MHRA
- Dyrupeg™ is a pegylated filgrastim biosimilar version
- This is CuraTeQ’s third biosimilar to be approved by MHRA
- Dyrupeg™ received marketing authorization in the European Union from the European Commission (EC) in April 2025
- CuraTeQ previously received approvals for Bevgolva™ in December 2024 and Zefylti™ in May 2025